Pfizer ($PFE) has entered the final phase of the late-stage COVID-19 vaccine trial. Thanks in part to a partnership with BioNTech ($BNTX), the two pharmaceutical companies are seen as market leaders and forerunners in the search of a COVID-19 vaccine. Pfizer yesterday announced a Phase III clinical trial involving 44,000 volunteers, which currently requires fewer than 2,000 people to be fully enrolled. In addition for the COVID-19 vaccine, an additional 36,000 people are fully dosed. This concerns two doses that require an interval of approximately 28 days.
|Vegas Winners Rolls Dice – Coming Soon – Buy This Stock ?|
|Buffett Sells Banks – Airlines – Buys Gold|
|Pandemic Play – Dillards Department Store Soars Ahead – Buffett Sniffing Around !|
Remarkable news is expected soon
Both Pfizer and BioNTech did not release any news today. For that reason, today’s gains are believed to be the result of a general rise in the stock market, that would have been boosted by better forecast growth in US Gross Domestic Product (GDP). Additionally, the BioNTech sell-off earlier this week showed a less sensitive response than initially thought. Shareholders are now waiting for the efficacy analysis, which is expected to be published shortly. The analysts have a positive feeling with which Pfizer and BioNTech can expect a huge boost in the third week of November. It is hoped that the pharmaceutical companies will submit an application for an EUA to the FDA for the mRNA-based COVID-19 vaccine BNT162b2.
Earlier, the end of October was predicted as the moment when most important data of the trial would be published, but this had to be postponed for several weeks due to circumstances. Analysts predict that the potential for an EUA filing with the FDA in November will remain feasible. It is almost certain that this will happen before the end of the year, subject to the results of clinical studies and subsequent approval by the EMEA. If this is succeeded in very short term, the vaccine may be available to the public before the New Year. Wider distribution is expected in the spring or summer of 2021.
Good behavior will be rewarded
BioNTech in particular has received a lot of praise for the way in which it has its affairs in order. In addition to all its research, the German company is busy drawing up detailed plans for health workers, the elderly and clinically vulnerable people. Pfizer on the other hand, is developing vaccine manufacturing programs and expects to have approximately 40 million doses by the end of this year, plus an additional 100 million doses by March 2021, capable of treating a total of 70 million people.
Finally, Pfizer has tightened a goal to provide a COVID-19 vaccine to less prosperous countries without willing to make a profit. For the United States, the COVID-19 vaccine is expected to cost $20 per dose unless the U.S. government has obtained the initial doses and will provide them to the public for free.
As a result today the shares of BioNTech were jumping 10.1% higher, while Pfizer started the morning well, but is now experiencing a stagnant phase.
More information and the efficacy analysis are expected soon, with the market’s main focus on the third week of November 2020. It could already be written down in the agenda.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.